CytomX Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CytomX Therapeutics (CTMX).

Price Target Range — 9 Quarters

Analyst Consensus — 10 Analysts

9Buy

1Hold

Consensus RatingOverweight# Analysts10Avg. Consensus PT$11Upside to Avg. PT+230.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	JP Morgan	Anupam Rama	PT Cut	Overweight	$12→$11
Aug 10, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$15→$14
May 11, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$17→$11
Mar 23, 2026	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$10→$12
Mar 19, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$10→$16
Mar 18, 2026	Jefferies	Roger Song	PT Raise	Buy	$8→$16
Mar 18, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$10→$15
Mar 17, 2026	Wedbush	Robert Driscoll	PT Raise	Outperform	$6→$11
Mar 16, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$10→$17
Mar 16, 2026	JP Morgan	Anupam Rama	Upgrade	Neutral→Overweight	$7→$12
Mar 9, 2026	Guggenheim	Michael Schmidt	Maintained	Buy	$10
Feb 4, 2026	Cantor Fitzgerald	Olivia Brayer	PT Raise	Overweight	$6→$10
Feb 4, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$8→$10
Jan 20, 2026	Barclays	Etzer Darout	PT Raise	Overweight	$6→$8
Jan 20, 2026	Guggenheim	Michael Schmidt	Initiate	Buy	$10
Jan 20, 2026	Piper Sandler	Joseph Catanzaro	PT Raise	Overweight	$7→$10
Nov 11, 2025	HC Wainwright & Co.	Mitchell S. Kapoor	PT Raise	Buy	$5→$10
Oct 21, 2025	Barclays	Etzer Darout	PT Raise	Overweight	$4→$6
Sep 22, 2025	Cantor Fitzgerald	Olivia Brayer	Initiate	Overweight	$6
Sep 17, 2025	Barclays	Etzer Darout	Assumes	Overweight	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.

Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $17 to $11.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $12.

Benzinga Newsdesk

PRO
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $10 to $16.

Benzinga Newsdesk

PRO
Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises the price target from $8 to $16.

Benzinga Newsdesk

CytomX Therapeutics Inc

CytomX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

PRO
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

PRO
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

PRO
Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

PRO
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

PRO
Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

People Also Watch

People Also Watch

Benzinga

Benzinga

CytomX Therapeutics Inc

CytomX Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROJP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

PROGuggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

PROHC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

PROPiper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

PROBarclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

PROJefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

People Also Watch

People Also Watch

PRO
JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11

PRO
Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

PRO
HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

PRO
Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

PRO
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

PRO
Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16